 |
|
Clinical Relevance of Bleeding Index—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We agree that the benefits of new antithrombotic agents must be weighed against their associated risks. In the fondaparinux trials, the difference in major bleeding observed between the 2 groups was mainly accounted for by an excess of "overt bleeding with a bleeding index of 2 or more."1 The clinical relevance of the bleeding index is uncertain. In our trials, the difference in the bleeding index between the fondaparinux and enoxaparin groups was not reflected by a difference in fatal bleeding, critical organ bleeding, bleeding leading to reoperation, and wound infection or complications at the surgical site leading to prolonged hospitalization or rehospitalization. It is noteworthy that when the first injection of fondaparinux was given between 6 and 8 hours after skin closure, as recommended in the US package insert, the rate of major bleeding decreased to 1.9%, a rate comparable with that observed with enoxaparin use (1.9%).
. . . [Full Text of this Article]
Alexander G. G. Turpie, MD, FRCP
Hamilton, Ontario
Kenneth A. Bauer, MD
Boston, Mass
Bengt I. Eriksson, MD, PhD
Göteborg, Sweden
Michael R. Lassen, MD
Hillerød, Denmark
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Clinical Relevance of Bleeding Index
Gerry Oster and Montserrat Vera
Arch Intern Med. 2003;163(22):2794.
EXTRACT
| FULL TEXT
Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery: A Meta-analysis of 4 Randomized Double-blind Studies
Alexander G. G. Turpie, Kenneth A. Bauer, Bengt I. Eriksson, Michael R. Lassen, and for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies
Arch Intern Med. 2002;162(16):1833-1840.
ABSTRACT
| FULL TEXT
|
